Inside SkinBit: How AI and Imaging Are Reshaping the Future of Skin Health

Crowdfunding Has Never Been This Easy

Invst Guru is your bi-weekly digest that explores the dynamics of equity crowdfunding. Delivered every Wednesday and Sunday, we connect startups with the power of the crowd, providing investors with access to groundbreaking ventures.

In each issue of Invst Guru, we'll spotlight the latest trends, share success stories, and offer insights from industry leaders. We aim to equip you with the knowledge and opportunities to participate effectively in equity crowdfunding, whether you're looking to fund your innovative startup or invest in potential unicorns.

🔬 Deal in Focus: SkinBit

Reimagining Skin Cancer Detection with AI, Vision, and Urgency

In 2020, Jonathan Benassaya faced a skin cancer diagnosis that changed the course of his life. The melanoma on his face was small—only 3mm—but the emotional and physical toll was anything but minor. Weeks passed in uncertainty. A sizable section of his face was removed as a precaution. That journey didn’t just leave a scar; it became the seed of a mission.

SkinBit is the product of that experience, but it’s also the outcome of a much broader challenge: millions of people each year are underserved by a dermatology system that cannot meet demand. SkinBit is developing an AI-powered full-body scanner to accelerate skin cancer screening, making it faster, more accessible, and potentially more accurate.

The company is currently engaging with the public through a Regulation Crowdfunding (Reg CF) campaign on Wefunder. Let’s examine the company, the market, and the momentum behind this mission.

📈 The Problem: 98 Million Americans, 48 Million Appointments

Skin cancer accounts for 75% of all cancer diagnoses in the U.S., affecting an estimated 3.6 million people annually. Despite this scale, dermatology capacity remains constrained. Only around 48 million appointments are available each year for screenings, which is half the number needed to serve the 98 million Americans who require annual checks due to age or medical history.

Wait times for dermatologists can stretch into months, especially in rural areas. This delay introduces risk: early detection significantly improves outcomes. Meanwhile, traditional visual assessments have known limitations; research suggests up to 25% of cancers may be missed, and false positives can reach 40%, leading to unnecessary biopsies and patient anxiety.

SkinBit’s founders believe scalable technology can help reduce friction in a system defined by scarcity and subjectivity.

🧠 The SkinBit Solution

SkinBit is developing a comprehensive skin scanning system that utilizes high-resolution imaging and proprietary AI to support skin evaluations. The system is designed to:

• Capture a full-body image at a SkinBit-equipped location

• Identify and flag lesions and moles

• Assess risk using AI trained on over 50,000 biopsy-confirmed images

• Deliver results to patients via a mobile app, after review by a licensed dermatologist

This establishes a digital skin health baseline for monitoring changes over time, aligning with best practices in preventive care. SkinBit’s training data comprises open-source and private clinical datasets, all of which have been verified by dermatological experts.

🧭 Market Landscape

SkinBit’s target market includes two primary groups: approximately 66 million Americans with a history of skin cancer and 32 million over the age of 65. These populations represent a substantial need for accessible, recurring screenings.

Rather than replacing dermatologists, SkinBit’s approach aims to extend their reach. Through a combination of automation, telehealth, and rapid triage, the system may help surface cases that require more urgent review, without overwhelming provider schedules.

The broader healthtech ecosystem is prioritizing early detection, and SkinBit’s approach could contribute to a more proactive and distributed care model. Clinics and MedSpas could also benefit from increased throughput without proportional staffing increases.

🛠 Deployment Strategy

SkinBit is initiating a launch phase utilizing a human-in-the-loop model, where board-certified dermatologists confirm all AI-assisted results. This supports near-term revenue generation while enabling the company to gather clinical data that may help future regulatory filings.

The anticipated regulatory roadmap includes:

• Clearance as a dermatologic imaging device (via 510(k))

• Subsequent clearance for autonomous AI interpretation

Scanners are deployed with a “scanner-as-a-service” model: clinics pay no upfront hardware cost, and SkinBit collects revenue from each completed scan. This recurring usage model enables distributed scaling and geographic expansion.

🧩 Strategic Infrastructure and Moats

SkinBit is building layered defensibility across:

• Data: An expanding dataset of verified, biopsy-backed skin imagery

• Distribution: A growing network of partner clinics equipped with SkinBit scanners

• Software: Patient-facing and provider-facing tools to streamline the skin health journey

• Brand: A narrative rooted in lived experience, not abstract opportunity

The team isn’t just delivering a device or app—they are building an integrated ecosystem to support ongoing skin monitoring, diagnostics, and patient engagement.

🔬 The Founding Team

Jonathan Benassaya, CEO – Serial entrepreneur and founder of Deezer (IPO on Euronext), StreamNation (acquired), with executive roles at Meta and Life360. His journey with melanoma informs the company’s mission.

Dr. Justin Ko, Chief Medical Advisor – Chief of Dermatology at Stanford, and a recognized researcher in AI-based dermatologic diagnostics.

Manuel Colom, CXO – Former Apple design lead with a focus on health tech accessibility and patient-centered design.

Together, the team combines startup execution with clinical leadership and design sophistication—essential ingredients for productizing care in a regulated environment.

🧬 The Patient Experience

Patients will be able to access SkinBit’s services through local clinics, imaging centers, or SkinBit-run facilities. The process is designed for convenience:

1. Visit a SkinBit-equipped location

2. Complete the scan in under 60 seconds

3. Review results on the mobile app

4. Connect with a licensed dermatologist as needed

Each scan contributes to a digital record, which can track longitudinal changes in skin health. Over time, this may provide value beyond cancer detection, supporting the management of chronic dermatologic conditions.

📊 Business Model

SkinBit’s revenue model is based on recurring usage. Scanners generate revenue per scan, not per device sale. This creates alignment with clinic operators and supports scale without upfront friction.

Use cases may include:

• Annual screenings for high-risk individuals

• Follow-up monitoring of previously biopsied lesions

• General skin health checkups for wellness consumers

While all future performance is subject to risk and uncertainty, the company believes that recurring medical needs and convenient access can help drive adoption over time.

⚖ Risk Factors & Considerations

As with any early-stage company, SkinBit faces key risks:

• Regulatory milestones: FDA clearance for AI autonomy will be required for future features

• Adoption: Clinic's willingness to adopt AI-assisted tools varies

• Capital needs: Continued development and growth will require additional investment

• Competition: Larger players may attempt similar approaches

Prospective investors should review the full risk disclosures on the Wefunder offering page.

🌍 Broader Implications

Skin cancer is one of the most common cancers, and one of the most preventable. By rethinking how screening is delivered, SkinBit aims to contribute to a more decentralized and preventive model of care.

If successful, the approach may help shift the burden of detection earlier in the care pipeline, benefiting both patients and the healthcare system.

💬 Final Thoughts

SkinBit is shaped by experience, driven by urgency, and grounded in clinical reality. The team’s vision is both personal and scalable: empower patients, support physicians, and unlock earlier detection through technology.

This campaign is live on Wefunder and open to the public under Regulation Crowdfunding. If the mission resonates, explore the full offering at the link below.

🔗 View the Campaign on Wefunder

📎 Required Disclaimers

Become a paying subscriber to get access to this post and other subscriber-only content.

Already a paying subscriber? Sign In.

The Signals. The Stories. The Startup Intel You Won’t Find Elsewhere.:

• • 1 just-launched Reg CF, Reg A, or Reg D campaign
• • 1 closing-soon raise — with momentum, context, and caveats
• • Clear breakdowns, red flags, standout metrics
• • No hype. Just the info serious investors want